Literature DB >> 30407981

Scheuermann's Kyphosis: Diagnosis, Management, and Selecting Fusion Levels.

Zeeshan M Sardar1, Robert J Ames, Lawrence Lenke.   

Abstract

Scheuermann's kyphosis (SK) is a rigid structural deformity of the thoracic spine defined radiographically as three or more contiguous vertebrae with at least 5° of wedging anteriorly. Prevalence of the disease is thought to be between 0.4% and 10%. The true cause of SK remains unclear; however, various theories include growth irregularities, mechanical factors, genetic factors, and/or poor bone quality as the causes. Patients with mild disease (less than 70°) generally have a favorable prognosis with good clinical outcomes. Most patients with SK are successfully treated nonsurgically with observation, anti-inflammatory medications, and physical therapy. Surgical intervention is indicated in patients with greater than 70° to 75° thoracic curves, greater than 25° to 30° thoracolumbar curves, intractable pain, neurologic deficit, cardiopulmonary compromise, or poor cosmesis. Because of advances in posterior spinal instrumentation, surgery can typically be performed through a posterior-only approach. When surgical treatment is planned, appropriate selection of the upper- and lower-instrumented vertebrae is important to achieve a well-balanced spine, preserve motion segments, and reduce the risk of junctional kyphosis.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30407981     DOI: 10.5435/JAAOS-D-17-00748

Source DB:  PubMed          Journal:  J Am Acad Orthop Surg        ISSN: 1067-151X            Impact factor:   3.020


  8 in total

1.  [Scheuermann's disease].

Authors:  Panagiotis Diaremes; Sebastian Braun; Andrea Meurer
Journal:  Orthopade       Date:  2022-03-15       Impact factor: 1.087

2.  Long-term outcome after surgical treatment of Scheuermann's Kyphosis (SK).

Authors:  Ujjwal K Debnath; Nasir A Quraishi; Michael J H McCarthy; J R McConnell; S M H Mehdian; Ali Shetaiwi; Michael P Grevitt; John K Webb
Journal:  Spine Deform       Date:  2021-09-17

3.  Evaluation of changes in kyphosis angle, apex and quality of life of patients with Scheuermann kyphosis using Kyphologic brace.

Authors:  Mohammad Reza Etemadifar; Masoud Mahdinezhad Yazdi
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-06-15

4.  Selection of the optimal distal fusion level for Scheuermann kyphosis with different curve patterns: when can we stop above the sagittal stable vertebra?

Authors:  Yanjie Xu; Zongshan Hu; Linlin Zhang; Abdukahar Kiram; Chen Ling; Zezhang Zhu; Yong Qiu; Zhen Liu
Journal:  Eur Spine J       Date:  2022-01-17       Impact factor: 2.721

5.  Assessment of Quality of Life for Scheuermann's Kyphosis Patients with Cobb's Angle 50°-65° Treated Conservatively or Surgically in North Jordan: A Prospective Comparative Study.

Authors:  Ziad Ali Audat; Khalid Ahmed Kheirallah; Bayan Faisal Ababneh; Hisham Zaidon Aljamal; Jomana Waleed Alsulaiman; Yaman Sameer Bataineh; Mohammad Moneer Algharibeh; Abdarrahman Ziad Audat
Journal:  Clin Orthop Surg       Date:  2022-03-03

6.  Can a Deep-learning Model for the Automated Detection of Vertebral Fractures Approach the Performance Level of Human Subspecialists?

Authors:  Yi-Chu Li; Hung-Hsun Chen; Henry Horng-Shing Lu; Hung-Ta Hondar Wu; Ming-Chau Chang; Po-Hsin Chou
Journal:  Clin Orthop Relat Res       Date:  2021-07-01       Impact factor: 4.755

7.  Cardiorespiratory function of patients undergoing surgical correction of Scheuermann's hyperkyphosis.

Authors:  Pablo Vera; Alejandro Lorente; Jesús Burgos; Pablo Palacios; Luis M Antón-Rodrigálvarez; Rocio Tamariz; Carlos Barrios; Rafael Lorente
Journal:  Sci Rep       Date:  2021-10-11       Impact factor: 4.379

8.  Septin7 is indispensable for proper skeletal muscle architecture and function.

Authors:  Mónika Gönczi; Zsolt Ráduly; László Szabó; János Fodor; Andrea Telek; Nóra Dobrosi; Norbert Balogh; Péter Szentesi; Gréta Kis; Miklós Antal; György Trencsenyi; Beatrix Dienes; László Csernoch
Journal:  Elife       Date:  2022-08-05       Impact factor: 8.713

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.